FDA record · warning letter

FDA warning letter: motionpharmacy.com (Sep 10, 2025)

On Sep 10, 2025, FDA issued a warning letter to motionpharmacy.com under the subject "Unapproved New Drug/Misbranded". It names semaglutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to motionpharmacy.com
Field	What FDA’s record states	Source
Recipient	motionpharmacy.com	FDA letter
Location	Not published by FDA	n/a
Letter date	Sep 10, 2025	FDA letter
Posted by FDA	Sep 23, 2025	FDA index
Issuing office	Center for Drug Evaluation and Research (CDER)	FDA letter
Subject	Unapproved New Drug/Misbranded	FDA letter
MARCS-CMS number	715595	FDA letter
GLP-1 drugs named	Semaglutide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“Finally, FDA has observed that www.motionpharmacy.com introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions. Injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.”FDA warning letter to motionpharmacy.com, Sep 10, 2025 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

And 48 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters